U.S. Markets open in 6 hrs 44 mins

AzurRx BioPharma, Inc. (AZRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.8732+0.0063 (+0.73%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8669
Open0.8603
Bid0.0000 x 1400
Ask0.0000 x 800
Day's Range0.8550 - 0.8835
52 Week Range0.6500 - 2.6300
Volume1,270,440
Avg. Volume2,655,779
Market Cap65M
Beta (5Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-1.4680
Earnings DateAug 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
  • AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital
    GlobeNewswire

    AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital

    BOCA RATON, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that James Sapirstein, Chief Executive Officer of AzurRx, will present at the 2021 BIO Digital. The virtual conference is taking place June 10-11 and June 14-18, 2021. Details of the event are as follows: Event: 2021

  • AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
    GlobeNewswire

    AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

    “RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline trial data expected in Q1 2022 BOCA RATON, Fla., June 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the administration of the first dose of FW-1022 to a volunteer in the ongoing Phase 2 RES

  • UPDATE - FMW Media, Inc.’s “New to The Street” TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET
    GlobeNewswire

    UPDATE - FMW Media, Inc.’s “New to The Street” TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET

    NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- FMW Media’s “New to The Street” TV broadcasting its national syndicated 1- hour show, Sunday, June 06, 2021 on NEWSMAX TV from 10-11AM ET. “New To The Street’s” TV Sunday line-up features 6 interviews of the following Companies and their businesses representatives: 1). Digital Development Partners’ (OTCMKTS: DGDM) and its subsidiary Black Bird Potentials’ interview with Mr. Eric Newlan, Vice-president and General Counsel, 2). AzurRx BioPharma, Inc.’s.